Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
By Michael Gibney,
PharmaVoice
| 03. 20. 2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and even cure diseases, that benefit carries risks. And although Elevidys has been used by more than 800 patients according to Sarepta, the recent death reflects concerns experts had with the therapy prior to its accelerated FDA approval in 2023 and full nod last year.
* * *
Despite a failed late-stage trial, Sarepta pointed to the treatment’s effect on secondary evidence of a functional mechanism of action. And Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, ultimately overruled regulatory staff and a review team when he expanded the therapy’s label to treat a wider range of patients.
The 16-year-old boy whose death was reported this week suffered from acute liver failure. While liver injury has been listed as a possible side effect of Elevydis and other gene therapies, no previous reaction was this severe...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...
By Hannah Devlin, The Guardian | 07.05.2025
Scientists are just a few years from creating viable human sex cells in the lab, according to an internationally renowned pioneer of the field, who says the advance could open up biology-defying possibilities for reproduction.
Speaking to the Guardian, Prof...
By Maoli Duan, The Conversation | 07.02.2025